Facile synthesis of novel nanocomposite prepared from spinel copper ferrite and reduced graphene oxide in the presence of anti-fouling agent diethyl ammonium acid sulphate for ultrasensitive detection of rosuvastatin in human plasma

• Published in: Microchemical journal Vol. 147; pp. 1133 - 1140
• Main Authors: El-Wekil, Mohamed M., Abdelhady, Khaled K., Abdel Salam, Randa A., Hadad, Ghada M., Ali, Ramadan
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.06.2019
• Subjects: Copper ferrite nanoparticles; Diethyl ammonium acid sulphate; Human plasma; Reduced graphene oxide; Rosuvastatin; Rosuvastatin; Copper ferrite nanoparticles; Human plasma; Reduced graphene oxide; Diethyl ammonium acid sulphate
• ISSN: 0026-265X; 1095-9149
• DOI: 10.1016/j.microc.2019.04.035

An innovative nanocomposite for the analysis of rosuvastatin (ROS) was constructed. The as synthesized nanocomposite composed of spinel copper ferrite nanoparticles (p-CuFeO2 NPs) supported on reduced graphene oxide (RGO) nanosheets in diethyl ammonium acid sulphate (DEAAS) as ionic liquid and anti-fouling agent. The prepared nanohybrid not only improves the interfacial electron transfer, but also readily exposed good catalytic effect toward ROS oxidation. The prepared sensor shows good oxidation behavior toward ROS oxidation in the range of 0.2–22.0 nM and the obtained LOD was 0.077 nM. To ensure good performance; the proposed sensor was used to determine ROS in different matrices and in human plasma. This study provides an efficient route to synthesize suitable nanohybrids for fabrication of potential sensors. Moreover, it opens new avenues in the manufacturing of ternary nanocomposite with excellent electrocatalytic effects. •Facile synthesis of novel CuFeO2/RGO/DEAAS for the first time.•The ternary nanocomposite has shown good electron transfer and excellent catalytic effect toward ROS oxidation.•The newly developed nanocomposite has shown high sensitivity and selectivity toward ROS analysis.•The method was used for detection of ROS during its pharmacokinetic study in human for the first time.